OTC Markets OTCPK - Delayed Quote USD
Kuros Biosciences AG (CSBTF)
32.40
0.00
(0.00%)
At close: May 1 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
75,555
75,555
33,564
17,986
13,815
Cost of Revenue
13,524
13,524
9,628
7,217
3,749
Gross Profit
62,031
62,031
23,936
10,769
10,066
Operating Expense
67,026
67,026
33,557
24,215
18,833
Operating Income
-4,995
-4,995
-9,621
-13,446
-8,767
Net Non Operating Interest Income Expense
474
474
2,145
-1,752
-787
Pretax Income
-3,346
-3,346
-9,776
-15,991
-9,554
Tax Provision
370
370
380
-1,396
-2,013
Net Income Common Stockholders
-3,716
-3,716
-10,156
-14,595
-7,541
Diluted NI Available to Com Stockholders
-3,716
-3,716
-10,156
-14,595
-7,541
Basic EPS
-0.25
-0.12
-0.38
-0.43
-0.23
Diluted EPS
-0.25
-0.12
-0.38
-0.43
-0.23
Basic Average Shares
36,905.03
37,198.53
36,582.02
33,900.69
32,794.13
Diluted Average Shares
36,905.03
37,198.53
36,582.02
33,900.69
32,794.13
Total Operating Income as Reported
-4,995
-4,995
-9,621
-13,446
-8,767
Total Expenses
80,550
80,550
43,185
31,432
22,582
Net Income from Continuing & Discontinued Operation
-3,716
-3,716
-10,156
-14,595
-7,541
Normalized Income
-3,716
-3,716
-10,156
-14,595
-7,541
Interest Income
163
163
400
29
596
Interest Expense
149
149
186
145
1,383
Net Interest Income
474
474
2,145
-1,752
-787
EBIT
-3,197
-3,197
-9,590
-15,846
-8,171
EBITDA
-561
-561
-6,838
-13,012
-5,291
Reconciled Cost of Revenue
13,524
13,524
9,628
7,217
3,749
Reconciled Depreciation
2,636
2,636
2,752
2,834
2,880
Net Income from Continuing Operation Net Minority Interest
-3,716
-3,716
-10,156
-14,595
-7,541
Total Unusual Items Excluding Goodwill
--
--
--
-3,600
--
Total Unusual Items
--
--
--
-3,600
--
Normalized EBITDA
-561
-561
-6,838
-13,012
-5,291
Tax Rate for Calcs
0
0
0
0
0
12/31/2021 - 4/17/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade